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Edited by Hans EklundAbstract The recently described Spred protein family has been
implicated in the modulation of receptor tyrosine kinase signal-
ling. We report the crystal structure of the Enabled/vasodila-
tor-stimulated phosphoprotein homology-1 (EVH1) domain
from Xenopus tropicalis Spred1, solved to 1.15 A˚ resolution.
This structure conﬁrms that the Spred EVH1 adopts the pleck-
strin-homology fold, with a similar secondary structure to
Enabled. A translation of one of the peptide-binding groove b-
strands narrows this groove, whilst one end of the groove shows
structural ﬂexibility. We propose that Spred1 will bind peptides
that are less proline-rich than other EVH1 domains, with confor-
mational changes indicating an induced ﬁt.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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phosphoprotein homology-1 domain; Peptide-binding1. Introduction
Members of the receptor tyrosine kinase (RTK) protein fam-
ily are heavily involved in fate decisions within both animal
development and in the maintenance of the adult animal,
and drive cellular processes including diﬀerentiation, migra-
tion, survival, proliferation, and metabolism [1,2]. Dysregula-
tion of RTK signalling has been implicated in a wide range
of human pathologies, most notably many cancers [3]. Re-
cently, a number of subtle intracellular protein modulators
of tyrosine kinase signalling have been identiﬁed. The related
Sprouty [4] and Spred [5] protein families have been character-
ised as such modulators. These two protein families share
homology in the cysteine-rich domains (Spry domain) at their
C-termini, and are conserved from Drosophila to humans [6,7].Abbreviations: EVH1, Enabled/VASP homology-1 domain; KBD, c-
Kit binding domain; MAPK, mitogen activated protein kinase; PH,
pleckstrin homology; RanBP, Ran binding protein; RTK, receptor
tyrosine kinase; VASP, vasodilator-stimulated phosphoprotein;
WASP, Wiskott–Aldrich Syndrome protein
q This structure has been submitted to the PDB under the code
1XOD.
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doi:10.1016/j.febslet.2004.11.114Both proteins have been shown to inhibit signalling down-
stream of RTKs, although the molecular basis of this inhibi-
tion remains unclear.
The three mammalian Spred homologues have been shown
to inhibit signalling via the small G-protein Ras and the
MAPK pathway, both in vitro [5,8] and in vivo [9]. The
Spred1 protein interacts with both Ras and Raf, probably
through the Spry domain [5,8]. The Spred family members
have two additional domains; an Enabled/vasodilator-stimu-
lated phosphoprotein (VASP) homology 1 (EVH1) domain
at the N-terminus, followed by a domain that is phosphory-
lated by the stem cell factor receptor c-Kit (Kit binding do-
main; KBD) that shows no similarity to other known
proteins [5]. The mammalian Spred3 has a non-functional
KBD and maintains the inhibitory action on Raf (albeit at
lower levels than other Spreds), indicating that the KBD is
not required for this action [8]. The EVH1 domain appears
to be more involved in Raf inhibition: replacement of the
murine Spred1 EVH1 domain with the Wiskott–Aldrich Syn-
drome protein (WASP) EVH1 domain abolished MAPK
inhibition [5]. However, Spred-2 was shown to be competent
to inhibit diﬀerentiation of murine haematopoietic cell lines
after deletion of the EVH1 domain [9]. Furthermore, the
EVH1 domains of the three mammalian paralogues are func-
tionally interchangeable [8]. These observations suggest that
the EVH1 domain does not act directly in the inhibitory
event, but regulates this activity.
EVH1 domains are a part of the pleckstrin homology (PH)
domain superfamily, a group of protein domains that share a
strikingly similar fold in spite of insigniﬁcant sequence simi-
larity. The Spred EVH1 domains form one of four subfam-
ilies in the well-characterised EVH1 family. All of the other
EVH1 subfamilies, and the related Ran binding protein
(RanBP) family, bind peptides in a cleft on the surface of
one b-sheet. The EVH1 domains (unlike RanBPs) appear
to have their activity entirely through this binding site. Phys-
iological ligands are known for three EVH1 subfamilies. All
three ligands are proline-rich sequences: the Enabled/VASP
family binds to FPPPP peptides, whilst PPxxF peptides bind
to the Homer/Vesl subfamily, and the WASP subfamily
binds to LPPPEP motifs [10,11]. In the WASP–peptide inter-
action, the peptide is in the opposite orientation to the com-
plex formed in the other two subfamilies. This indicates that
binding of the peptide in both directions is possible in this
protein family, as has previously been observed for the
SH3 family of polyproline binding domains [12]. To date,blished by Elsevier B.V. All rights reserved.
Table 1
Crystallographic data
1162 N.J. Harmer et al. / FEBS Letters 579 (2005) 1161–1166no ligand has been proposed for the Spred EVH1 domains,
nor have direct interactions to other proteins been
demonstrated.
We here report the crystal structure of the Spred1 EVH1
domain from Xenopus tropicalis, the ﬁrst structure of an
EVH1 domain from the Spred subfamily. The overall fold
is highly conserved with the other EVH1 domains. The struc-
ture reveals diﬀerences in the peptide binding site that suggest
that the peptide sequence consensus may be diﬀerent from the
other EVH1 subfamilies. The peptide-binding groove is some-
what narrower than homologous structures, suggesting that a
less proline-rich sequence will bind. Diﬀerences at one end of
the groove in the two molecules in the asymmetric unit sug-
gest that this region may have an induced ﬁt with the peptide.
These observations suggest that the Spreds are likely to form
a fourth distinct peptide binding mechanism within the EVH1
family.
Space group P21
Unit cell parameters a = 32.81, b = 38.01,
c = 79.91, b = 95.68
Wavelength (A˚) 0.975
Resolution (A˚) 22 – 1.15
Reﬂections (unique) 68977
Redundancy (outer shell) 3.9 (3.5)
Completeness (%) (outer shell) 97.9 (94.5)
Rsym (%)
a (outer shell) 6.9 (35.1)
I/r(I) (outer shell) 19.4 (3.99)
No. of non-H atoms 2134
Overall R factor (working + test, %)b 15.5
Working R factor (%) 15.4
Free R factor (%)c 17.7
Average B (A˚2) 12.5
Average B, main chain (A˚2) 9.34
Average B, side chain (A˚2) 10.9
Average B, water 23.9
RMSD bonds (A˚) 0.009
RMSD angles () 1.35















cThe free R factor was calculated from 5% of the data.
Fig. 1. Overview of X. tropicalis Spred1 EVH1 domain structure. (a)
Cartoon of secondary structure. Helices are shown as rectangles, b-
strands as arrows. Structure is shown with the front sheet of the b-
sandwich rotated about a hinge at the top of the sandwich, represented
by the dotted grey line. The front sheet is shown in light grey, the back
sheet in dark grey. The b4–b5 loop is broken to rotate the top sheet,
and is shown by broken line. (b) Comparison of the two molecules
observed in the asymmetric unit. Structures are shown in the cartoon
representation. The lower view is rotated by 180 about the vertical
axis. Dark grey: molecule A; light grey: molecule B.2. Materials and methods
2.1. Chemicals
Chemicals were obtained from Sigma, Melford Laboratories, or
Fisher Scientiﬁc.
2.2. Expression and puriﬁcation of X. tropicalis Spred1 EVH1 domain
DNA corresponding to amino acids 8–123 of X. tropicalis Spred1
and an N-terminal thrombin cleavage site was cloned into the
pETG-10a vector (a gift of A. Geerlof and EMBL laboratories,
Hamburg) using GATEWAY technology (Invitrogen). Expression
was performed in the ER2566 Escherichia coli strain (New England
Biolabs). The Spred1 EVH1 domain was bound to a 1 ml HisTrap
column (Amersham Biosciences) in a buﬀer of 20 mM Tris–HCl,
pH 8.0, 0.5 M NaCl, and eluted with a gradient to 250 mM imidaz-
ole. The eluate was digested with thrombin to remove the polyhisti-
dine tag. After adding ammonium sulphate to 1.5 M, the Spred1
EVH1 domain was bound to a phenyl–Sepharose column (Amer-
sham), and eluted using a gradient to 20 mM Tris–HCl pH 8.0.
The protein was then applied to a Superdex 75 size exclusion column
(Amersham) and eluted using a buﬀer of 100 mM NaCl, 10 mM Tris–
HCl, pH 8.0, and 5 mM DTT.
2.3. Crystallisation of Spred1 EVH1 domain and structure solution
X. tropicalis Spred1 EVH1 domain crystallised using a mother liquor
of 19–20% (w/w) PEG 3350, 0.2 M KF at 18 C. Diﬀraction quality
crystals grew over 7–14 days. Crystals were cryoprotected with the
addition of 15% glycerol to the mother liquor. Data were collected
to 1.15 A˚ at the Daresbury Synchrotron Radiation Source, station
PX14.2, at 100 K. X-ray data were indexed and scaled using the
HKL package [13]. To provide phases, structures of Enabled and
Homer (PDB codes 1EVH, 1I7A, and 1QC6) were superimposed
and altered as described [14] for use as a search model for AMORE
[15], searching for two molecules in the asymmetric unit. This provided
a solution that gave suﬃciently good phases for model building. Phases
were improved using Arp/Warp [16] to add water to the initial model.
Following this, the remainder of the model was built by hand, using
the Xtalview viewer [17]. Reﬁnement was carried out ﬁrst using CNS
[18] and then Refmac [19] at the later stages. The model was validated
using PROCHECK [20], WHATCHECK [21], and MOLPROBITY
[22].
2.4. Analysis of protein structure
The structures of other EVH1 and RanBP domains were obtained
from the Protein Data Bank [23] (Enabled: PDB code 1EVH; WASP:
1DDV; Homer: 1MKE; RanBP: 1K5D). Structural alignments were
prepared using COMPARER [24]. Additional sequences were added
using CLUSTALX [25] and FUGUE [26]. The alignment was then
hand-edited. Structural superpositions were performed using LSQ-
MAN [27]. Images were prepared using PYMOL [28].3. Results and discussion
3.1. Structure determination
Residues 8–123 of X. tropicalis Spred1 were expressed with a
6-His tag in E. coli. Following aﬃnity puriﬁcation to immobi-
lised metal ions, the tag was removed, and the Spred1 EVH1
domain puriﬁed to homogeneity by hydrophobic interaction
and size exclusion chromatography. Diﬀraction quality crys-
tals grew over one to two weeks in a mother liquor of
19–20% (w/w) PEG 3350, 0.2 M KF. Initial phases were pro-
vided using molecular replacement with previously solved
EVH1 domains, and reﬁnement was performed using standard
methods. The ﬁnal model consists of two Spred1 EVH1
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The four most N-terminal residues, and residues 44–52, of
molecule A could not be resolved. Data collection and reﬁne-
ment statistics are shown in Table 1.
3.2. Global structural comparison
The Spred1 EVH1 domain is comprised of two b-sheets that
form a b-sandwich, with one end capped by aC-terminal a-helix
(Fig. 1(a)). There is an RMSD of 1.54 A˚ between the backbone
Cas of the twomolecules in the asymmetric unit, with diﬀerences
mainly at crystal contact sites. The most interesting diﬀerence
occurs at the interaction between both R75 and the C-terminus
of molecule A and the b1–b2 loop of molecule B, altering the
conformation of this loop. This latter loop consists solely of ser-
ine, glycine, and aspartate residues (Fig. 2(a)), suggesting that
conformational ﬂexibility may be a structural feature.
Comparison of the X. tropicalis Spred1 structure with other
EVH1 domains shows that the secondary structure is well
conserved within the family (Fig. 2(b) and (c)). The Spred1Fig. 2. Global comparison of X. tropicalis. Spred1 EVH1 domain with other E
sequences and structures from Enabled, Homer, WASP, RanBP and Spreds. F
structures, equivalent to M19, R21, W28 and F86, are highlighted with
structures. Cartoon representation is shown. Lower view is rotated by 180 a
B, green; Enabled, blue; Homer, purple; WASP, black; RanBP, cyan. (d) The
comparison to other EVH1 domains. Strands 2 0 and 3 and the loop are show
light red. Colours as in (b).EVH1 domain has a short 310 helix between strands b2 and
b2 0, a feature that is shared with Enabled, but not with other
EVH1 domains (Fig. 2(a) and (c)). The extended, ﬂexible
loop between b2 0 and b3 is considerably longer than the
equivalent loops in other structures from the EVH1 family,
all of which are well ordered (Fig. 2(a) and (d)). Further-
more, the sequence of the loop is diﬀerent in every position
except one from the sequence of human Spred-1 (Fig. 2a),
whereas these sequences are highly similar throughout the
remainder of the sequence. This, and the apparent ﬂexibility
of the loop, suggests that it is unlikely to be functionally
relevant.
3.3. Structural investigation of the Spred EVH1 domain
peptide-binding site
The EVH1 domains express their activity principally by
binding peptides in a groove that lies between strands b1, b2,
b6 and b7. Although previous analyses have shown that
replacement of the Spred EVH1 domain with the WASPVH1 and RanBP structures. (a) Structural alignment of EVH1 domain
igure prepared using JOY [29]. Key ligand binding residues from other
black arrowheads. (b,c) Global superposition of EVH1 and RanBP
bout a vertical axis. Colours: Spred1 molecule A, red; Spred1 molecule
Spred1 b2 0–b3 loop (black arrowhead) shows considerable extension in
n for all molecules, with the remainder of Spred1 molecule A shown in
1164 N.J. Harmer et al. / FEBS Letters 579 (2005) 1161–1166domain abolishes Raf inhibition [5], we examined the Spred
peptide-binding groove to determine whether the peptide
might bind in a manner analogous to a homologous structure.
The Spred1 EVH1 domain structures were superimposed onto
those of EVH1 domain–peptide complexes, using the Ca posi-
tions in strands b1, b2, b6, and b7. In each case, the peptide
clashes with the surface of the Spred molecule (Fig. 3). The
best ﬁt is seen with the Homer peptide (Fig. 3(c) and (d)),
where the only clashes are observed at the C-terminus of the
peptide. The surface to which this peptide binds on Spred is
conserved between the molecules in the crystal structure, sug-
gesting that there is little ﬂexibility in this region. In the cases
of the Enabled and WASP peptides, there are clashes betweenFig. 3. Comparison of the Spred1 peptide-binding groove with other EVH
superimposed onto the Spred1 structures, using strands b1, b2, b6 and b7 to s
view) are shown. (a,c,e): Spred1 molecule A. (b,d,f): Spred1 molecule B. a,b:
nitrogen, blue; oxygen: red; Spred carbon, green; Enabled carbon, cyan
representation of Spred1 molecule A in identical conformation, coloured blu
by approximately 45 relative to other ﬁgures.peptide proline side chains and the Spred molecules (Fig. 3(a),
(b), (e), (f)). These clashes are more pronounced in molecule B,
due to the change in the conformation of the b1–b2 loop. Mol-
ecule A also shows a slightly larger pocket at the lower pep-
tide-binding surface (Fig. 3(a)). These changes suggest that
the lower side of the peptide-binding groove (as viewed in
Fig. 3) is somewhat ﬂexible in conformation and that the true
peptide-binding conformation is induced upon peptide
binding.
In addition to providing a complementary surface, pep-
tide-binding proteins provide hydrogen bond donors and
acceptors to satisfy the peptide main-chain amide and car-
boxyl groups. In the EVH1 family, a key conserved trypto-1 domains. Enabled, Homer and WASP complexes with peptide were
uperimpose. Spred surface (calculated by PYMOL) and peptide (sticks
Enabled peptide. (c,d): Homer peptide. (e,f): WASP peptide. Colours:
; Homer carbon, magenta; WASP carbon, yellow. Inset: cartoon
e to red from N- to C-terminus. c,d are rotated about a horizontal axis
Fig. 4. Detail of key peptide binding residues (a) Comparison of the
positions of active site side chains. Strands b1, b2 and b7 are shown for
all molecules, with the remainder of Spred1. W28 and F86 are shown as
sticks. Backbone location of selected residues is shown by white text.
Colours: Spred1, red (light red outside peptide-binding groove);
Enabled, blue; Homer, purple; WASP, black; nitrogen, blue (blue-
grey: Spred1, cyan: Enabled); oxygen, red. Spred W28, yellow
arrowhead. Homologous tryptophans, grey arrow. F86, black arrow.
(b) The Spred1 strand b2 is translated in comparison to the other EVH1
domains. Strands b1, b2 and b2 0 are shown all molecules, with the
remainder of Spred1. Spred strand b2, black arrow; Other EVH1 strand
b2, dashed arrow. Colours as in (a). (c) Comparison of Y21 equivalents
in the two Spred1 structures. W28 and R/Y21 are shown as sticks.
Colours as in (a), Spred1 molecule B in green. Enabled Y21, grey arrow.
Spred1 R21 (two conformations), black and yellow arrows.
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surface and a hydrogen bond donor. In the Spred1
structure, this tryptophan (W28) is displaced relative to the
peptide-binding site, with a shift of 1.57 A˚ in the indole
nitrogen compared with Enabled (Fig. 4(a)). This translation
is observed when the domain is compared to both
liganded and unliganded EVH1 domains (data not shown),
and is observed in the entirety of sheet b2 (on which W28
is located; Fig. 4(b)), suggesting that this is not an artefact
of ligand binding. Alterations in this side chain have not
been observed previously: the tryptophan conformation is
invariant in the other three classes of EVH1 domains, and
a W28A mutation in the WASP protein leads to domain
misfolding. This translation is likely to require a similar
translation of the peptide, to take advantage of the
hydrogen bond donor and the hydrophobic surface: this
suggests that a signiﬁcant alteration in the peptide confor-
mation will be required compared to the other EVH1
domains.
In addition to W28, other EVH1 domains absolutely con-
serve F86 at the top of the peptide-binding groove, and have
an extra aromatic side chain at position 19 or 21 at the bottom
of the groove (Fig. 2(a)). Spred1 maintains F86, with a very
similar conformation to that of other EVH1 domains (Fig.
4(a)), contributing to the stable and well-conserved upper face
of the groove. In contrast, Y21 is substituted for a conserved
arginine in the Spreds (Fig. 4(c)). In the Homer and WASP
EVH1 domains, which bind peptides with less extensive
polyproline helices than Enabled, Y21 is substituted for smal-
ler side chains: however, an aromatic side chain is present at
amino acid 19 to form an alternative hydrophobic pocket.
The Spred proteins have a conserved methionine in position
19, suggesting that a similar pocket is unlikely to be formed.
The more ﬂexible side chains of the Spreds suggest that this
face of the binding pocket is less structurally rigid than other
EVH1 domains.
These observations suggest two possibilities for the bind-
ing of peptides to the Spred EVH1 domains. One is a pep-
tide binding in a similar manner to the Homer peptide (Fig.
3(c) and (d)), binding to the apparently conformationally
stable upper end of the peptide-binding groove. A somewhat
diﬀerent conformation to the peptide is likely to be neces-
sary due to the diﬀerent pattern of hydrogen bond donors
and acceptors. Alternatively, an extended peptide passing
through the entire groove, in the manner of Enabled or
WASP could bind (Fig. 3(a), (b), (e), and (f)). Due to the
translation of strand b2 and W28, a change in conformation
will be necessary to permit such binding. This requirement,
together with the clashes of proline side chains with the
Spred1 surface, suggest that a less proline-rich peptide will
be necessary to bind with a high aﬃnity. Speciﬁcity and
aﬃnity in this case are likely to be provided by an induced
ﬁt of the conformationally ﬂexible lower face of the peptide-
binding groove to this end of the peptide. The EVH1 do-
mains of the Spred family are likely to be key either to
the inhibition of the MAPK pathway, or to the regulation
of this inhibition. The identity of the binding partners to
this domain is likely to considerably enlighten the molecular
mechanism for the modulation of RTK signalling by the
Sprouty and Spred protein families, and to improve our
understanding of how the RTK system provides a robust
signalling network.
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